See more : Asset Entities Inc. (ASST) Income Statement Analysis – Financial Results
Complete financial analysis of Arcadia Biosciences, Inc. (RKDA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arcadia Biosciences, Inc., a leading company in the Agricultural Inputs industry within the Basic Materials sector.
You may be interested
- Shanghai Zhezhong Group Co.,Ltd (002346.SZ) Income Statement Analysis – Financial Results
- 420 Property Management, Inc. (FTPM) Income Statement Analysis – Financial Results
- Nevada Sunrise Metals Corporation (NEV.V) Income Statement Analysis – Financial Results
- FranceSoir Groupe SA (MLFSG.PA) Income Statement Analysis – Financial Results
- Under Armour, Inc. (UAA) Income Statement Analysis – Financial Results
Arcadia Biosciences, Inc. (RKDA)
About Arcadia Biosciences, Inc.
Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The company was incorporated in 2002 and is headquartered in Davis, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.33M | 9.96M | 6.78M | 8.03M | 1.17M | 1.46M | 4.03M | 3.19M | 5.41M | 6.98M | 6.48M | 7.01M |
| Cost of Revenue | 3.30M | 9.80M | 8.71M | 5.20M | 885.00K | 661.00K | 283.00K | 895.00K | 892.00K | 2.00M | 673.00K | 909.00K |
| Gross Profit | 2.03M | 154.00K | -1.93M | 2.84M | 284.00K | 803.00K | 3.74M | 2.29M | 4.52M | 4.99M | 5.81M | 6.10M |
| Gross Profit Ratio | 38.09% | 1.55% | -28.44% | 35.29% | 24.29% | 54.85% | 92.97% | 71.93% | 83.52% | 71.40% | 89.61% | 87.03% |
| Research & Development | 1.39M | 1.51M | 3.89M | 7.96M | 7.10M | 6.07M | 7.41M | 8.66M | 8.97M | 10.01M | 8.40M | 7.95M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 16.47M | 13.57M | 11.60M | 10.65M | 12.25M | 11.12M | 10.13M | 7.97M | 8.28M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.51M | 18.05M | 22.94M | 16.47M | 13.57M | 11.60M | 10.65M | 12.25M | 11.12M | 10.13M | 7.97M | 8.28M |
| Other Expenses | 73.00K | 33.00K | 10.11M | 105.00K | 466.00K | -3.61M | 281.00K | 340.00K | 521.00K | 0.00 | 5.00K | 8.00K |
| Operating Expenses | 15.90M | 19.56M | 26.83M | 24.43M | 20.67M | 17.67M | 18.06M | 20.91M | 20.09M | 20.14M | 16.37M | 16.23M |
| Cost & Expenses | 19.27M | 29.36M | 35.54M | 29.63M | 21.55M | 18.33M | 18.34M | 21.81M | 20.98M | 22.14M | 17.04M | 17.14M |
| Interest Income | 695.00K | 289.00K | 20.00K | 47.00K | 5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 289.00K | 20.00K | 47.00K | 5.00K | 0.00 | 747.00K | 1.32M | 2.66M | 1.39M | 626.00K | 186.00K |
| Depreciation & Amortization | 287.00K | 1.36M | 1.04M | 662.00K | 194.00K | 154.00K | 279.00K | 304.00K | 294.00K | 358.00K | 391.00K | 378.00K |
| EBITDA | -13.58M | -13.65M | -23.27M | -5.44M | -28.67M | -13.32M | -14.66M | -17.98M | -14.98M | -15.39M | -10.17M | -9.74M |
| EBITDA Ratio | -254.75% | -228.21% | -270.87% | -259.21% | -1,747.56% | -1,562.64% | -341.65% | -563.86% | -272.40% | -211.90% | -156.99% | -139.00% |
| Operating Income | -13.94M | -19.40M | -35.53M | -21.59M | -20.38M | -16.87M | -14.32M | -18.62M | -15.56M | -15.15M | -10.57M | -10.13M |
| Operating Income Ratio | -261.50% | -194.89% | -523.98% | -268.76% | -1,743.46% | -1,152.32% | -355.56% | -584.07% | -287.46% | -217.03% | -163.11% | -144.51% |
| Total Other Income/Expenses | 781.00K | 3.19M | 19.39M | 6.63M | -9.49M | 3.40M | -1.37M | -979.00K | -2.37M | -1.99M | -621.00K | -178.00K |
| Income Before Tax | -13.16M | -15.60M | -16.13M | -6.15M | -28.87M | -13.47M | -15.68M | -19.60M | -17.93M | -17.14M | -11.19M | -10.31M |
| Income Before Tax Ratio | -246.85% | -156.67% | -237.94% | -76.55% | -2,469.72% | -920.08% | -389.49% | -614.77% | -331.18% | -245.55% | -172.69% | -147.05% |
| Income Tax Expense | 8.00K | 14.00K | 2.00K | -124.00K | 2.00K | 10.00K | 26.00K | 25.00K | 26.00K | 263.00K | 167.00K | 213.00K |
| Net Income | -13.98M | -15.61M | -16.13M | -6.03M | -28.87M | -13.48M | -15.71M | -19.62M | -17.96M | -18.34M | -13.20M | -12.37M |
| Net Income Ratio | -262.31% | -156.81% | -237.96% | -75.01% | -2,469.89% | -920.77% | -390.14% | -615.56% | -331.66% | -262.66% | -203.69% | -176.46% |
| EPS | -11.30 | -26.05 | -30.33 | -24.20 | -181.50 | -143.16 | -291.38 | -353.85 | -503.00 | -448.39 | -322.62 | -302.44 |
| EPS Diluted | -11.30 | -26.05 | -30.33 | -24.20 | -181.50 | -143.16 | -291.38 | -353.85 | -503.00 | -448.39 | -322.62 | -302.44 |
| Weighted Avg Shares Out | 1.24M | 599.39K | 532.02K | 248.98K | 159.08K | 94.16K | 53.91K | 55.46K | 35.70K | 40.90K | 40.90K | 40.90K |
| Weighted Avg Shares Out (Dil) | 1.24M | 599.39K | 532.02K | 248.98K | 159.08K | 94.16K | 53.91K | 55.46K | 35.70K | 40.90K | 40.90K | 40.90K |
Arcadia Biosciences (RKDA) Q2 Earnings Miss, Increase Y/Y
Arcadia Biosciences (RKDA) witnesses a solid 42% improvement in Zola sales in Q2. The company continues to invest to grow the Zola brand through mass market retailers and grocery store chains.
Arcadia Biosciences, Inc. (RKDA) Q2 2024 Earnings Call Transcript
Arcadia Biosciences, Inc. (NASDAQ:RKDA ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Mark Kawakami - CFO T.J. Schaefer - President & CEO Conference Call Participants Raghuram Selvaraju - H.C.
Arcadia Biosciences (RKDA) Q2 Earnings Miss Estimates
Arcadia Biosciences (RKDA) came out with quarterly earnings of $0.78 per share, missing the Zacks Consensus Estimate of $1.27 per share. This compares to loss of $2.64 per share a year ago.
Arcadia Biosciences (RKDA) Announces Second-Quarter and First-Half 2024 Financial Results and Business Highlights
DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the second quarter and first half of 2024. “The second quarter of 2024 was a...
Prime Therapeutics Fails to Silence AHF in PBM Price-Fixing Arbitration
LOS ANGELES--(BUSINESS WIRE)--Prime Therapeutics Fails to Silence AHF in PBM Price-Fixing Arbitration.
Arcadia Biosciences (RKDA) Announces Date of Second Quarter 2024 Financial Results and Business Highlights Conference Call
DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial and business results for the second quarter and first half of 2024 after market close...
Arcadia Biosciences (RKDA) Upgraded to Strong Buy: Here's What You Should Know
Arcadia Biosciences (RKDA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
The Cheesecake Factory Offers Triple the Reasons to Celebrate National Cheesecake Day This Year
CALABASAS HILLS, Calif.--(BUSINESS WIRE)--The Cheesecake Factory® is celebrating its favorite holiday – National Cheesecake Day – in a big way this year making it a two-day celebration and introducing the newest flavor to its legendary lineup on July 29: Triple...
Arcadia Biosciences (RKDA) Announces Leadership Transition
DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced that CEO Stan Jacot has left the company and been replaced by Thomas J. Schaefer, effective July 5, 2024. Schaefer was previously...
Arcadia Biosciences (RKDA) Sells GoodWheat Brand to Above Food
Arcadia Biosciences (RKDA) sells its GoodWheat brand to scale up its wheat IP.
Source: https://incomestatements.info
Category: Stock Reports